Agilent Technologies, Inc. (A)

Agilent beat expectations on both the top and bottom line in the third fiscal quarter of 2026, based on preliminary results reported August 26, 2026, with adjusted EPS of $1.62 topping the $1.49 estimate (+8.7%) and revenue of $1.878 billion topping the $1.841 billion estimate (+2%). Revenue rose ~8% to about $1.9 billion (up from about $1.7 billion a year ago), reflecting demand across its Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab businesses. Profitability translated into GAAP operating income of roughly $444 million, while net income increased ~8% to about $362 million (up from roughly $336 million a year ago). On the bottom line, adjusted EPS rose ~18% from $1.37 a year ago to $1.62. The company generated operating cash flow of about $519 million and returned cash through roughly $78 million of share repurchases alongside about $72 million in dividends. For the next period, consensus calls for EPS of $1.71 on revenue of $1.975 billion.